Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivir
Description
Global Hepatitis Drugs Market, By Drug Class (Interferon Alphas, HIV NRTIs, Nucleotide Polymerase/NS5A Inhibitor Combinations, Hepatitis C Protease/NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, and Thrombopoiesis Stimulating Agents), By Disease Type (Hepatitis B, Hepatitis C, and Others), By Route of Administration (Oral and injection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.
Market Dynamics
Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.
However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.
Key features of the study:
This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hepatitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Hepatitis Drugs Market, By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
Global Hepatitis Drugs Market, By Disease Type:
Hepatitis B
Hepatitis C
Others
Global Hepatitis Drugs Market, By Route of Administration:
Oral
Injection
Global Hepatitis Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hepatitis Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Interferon Alphas
HIV NRTIs
Hepatitis B NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Merck & Co. Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Gilead Sciences Inc.
AbbVie Inc.
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
LAURUS Labs
Zydus Cadila
Hetero Healthcare Limited
GlaxoSmithKline PLC
Cipla Inc.
“*” marked represents similar segmentation in other categories in the respective section
Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.
Market Dynamics
Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.
However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.
Key features of the study:
This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hepatitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
Global Hepatitis Drugs Market, By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
Global Hepatitis Drugs Market, By Disease Type:
Hepatitis B
Hepatitis C
Others
Global Hepatitis Drugs Market, By Route of Administration:
Oral
Injection
Global Hepatitis Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hepatitis Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Interferon Alphas
HIV NRTIs
Hepatitis B NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country:
South Africa
Central Africa
North Africa
By Drug Class:
Interferon Alphas
HIV NRTIs
Nucleotide Polymerase / NS5A Inhibitor Combinations
Hepatitis C Protease / NS5A Inhibitor Combinations
NS5A Inhibitors
Nucleotide Polymerase Inhibitors
Nucleoside Analogue Antivirals
Thrombopoiesis Stimulating Agents
By Disease Type:
Hepatitis B
Hepatitis C
Others
By Route of Administration:
Oral
Injection
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
Merck & Co. Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Gilead Sciences Inc.
AbbVie Inc.
Bristol Myers Squibb Company
F. Hoffmann-La Roche Ltd.
LAURUS Labs
Zydus Cadila
Hetero Healthcare Limited
GlaxoSmithKline PLC
Cipla Inc.
“*” marked represents similar segmentation in other categories in the respective section
Table of Contents
173 Pages
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Landscape
- Epidemiology Analysis
- Reimbursement Scenario
- PEST Analysis
- 4. Global Hepatitis Drugs Market, By Drug Class, 2017 - 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Interferon Alphas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- HIV NRTIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Hepatitis C Protease / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Nucleotide Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Nucleoside Analogue Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Thrombopoiesis Stimulating Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 5. Global Hepatitis Drugs Market, By Disease Type, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hepatitis B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 6. Global Hepatitis Drugs Market, By Route of Administration, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 7. Global Hepatitis Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2028(%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
- 8. Global Hepatitis Drugs Market, By Region, 2017 - 2028, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2022 and 2028(%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
- North America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)l
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
- 9. Competitive Landscape
- Company Profiles
- Merck & Co. Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Gilead Sciences Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bristol Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- LAURUS Labs
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hetero Healthcare Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- GlaxoSmithKline PLC.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Cipla Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- 10. Section
- References
- Research Methodology
- About Us and Sales Contact
- *Browse 35 market data tables and 27 figures on "Global Hepatitis Drugs Market” - Global forecast to 2028”
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
